HealthcareServices

Viral And Non-Viral Vector Manufacturing Market Dynamics 2026: Future Outlook and Key Insights

March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the viral and non-viral vector manufacturing market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Viral And Non-Viral Vector Manufacturing Market expected to reach by 2030?

The market size for viral and non-viral vector manufacturing has experienced substantial expansion in recent years. This market is projected to grow from $10.28 billion in 2025 to $12.4 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.7%. The increase witnessed in the historic period can be ascribed to advancements in gene therapy research, heightened clinical trial activity, the enlargement of biopharmaceutical manufacturing facilities, a rising demand for viral vectors in oncology, and the availability of specialized manufacturing expertise.

The viral and non-viral vector manufacturing market is projected to experience substantial expansion in the coming years, with its size forecast to reach $26.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 21.3%. This anticipated growth is driven by several factors, including the increasing commercialization of gene and cell therapies, heightened investments in vaccine development, the expansion of CDMO collaborations, a greater emphasis on scalable and adaptable manufacturing processes, and a rise in regulatory approvals for advanced therapies. Key trends anticipated during this period involve the scaling up of viral vector production capacity, an increasing need for non-viral delivery systems, the growing implementation of modular manufacturing platforms, the expansion of outsourced vector manufacturing services, and a strengthened focus on standardizing processes and ensuring quality control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp

What Drivers Are Driving Adoption Within The Viral And Non-Viral Vector Manufacturing Market?

The growing number of clinical trials is anticipated to fuel the expansion of the viral and non-viral vector manufacturing markets. Clinical trials are investigative studies performed with human participants to assess the safety, effectiveness, and potential adverse effects of medical interventions, treatments, or drugs. Viral and non-viral vector manufacturing is crucial for facilitating gene therapy clinical trials, as it supplies the necessary tools for delivering therapeutic genes to patients and guarantees the safety, quality, and scalability of these vectors throughout the various trial phases. For example, data from ClinicalTrials.gov, a US-based web resource maintained by the US National Library of Medicine, indicated in December 2023 that in the year 2022, a total of 437,515 clinical trials were registered, with 56,561 of them having been completed. By December 20, 2023, both registration and completion figures showed an increase, with 476,626 clinical trials registered and 61,504 trials completed. As a result, the escalating number of clinical trials is significantly boosting the growth of the viral and non-viral vector manufacturing markets.

What Segments Are Included Within The Viral And Non-Viral Vector Manufacturing Market?

The viral and non-viral vector manufacturing market covered in this report is segmented –

1) By Vector Type: Viral Vector, Non-Viral Vector

2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases

3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications

Subsegments:

1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors

2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors

What Trends Are Expected To Impact The Competitive Landscape Of The Viral And Non-Viral Vector Manufacturing Market?

Major companies in the viral and non-viral vector manufacturing market are increasingly focusing on partnerships to enhance their profitability. Collaborative ventures in viral and non-viral vector manufacturing involve biopharmaceutical companies, CDMOs, research institutions, and technology providers working together to improve the efficiency, safety, and scalability of non-viral vector development and production. For instance, in September 2023, NecstGen, a Netherland-based CDMO offering comprehensive support for Cell and Gene Therapy developers, collaborated with ProteoNic BioSciences, a Netherland-based technology provider for complex therapeutic protein production, to launch ProteoNic’s 2G UNic premium vector technology. The successful implementation of this technology has optimized the development of lentiviral (LV) vectors, increasing functional viral particle titers and directly boosting process efficiency, thereby improving the cost-effectiveness and accessibility of therapies. This versatile technology extends to various applications, including gene therapy viral vector production, mRNA therapeutics, and transient protein production. By advancing AAV and LV viral vector manufacturing technology for both transient systems and stable producer cell lines, this development has the potential to benefit viral vector manufacturing for gene therapies and non-vector processes, offering advantages across diverse applications.

Who Are The Top-Performing Companies In The Viral And Non-Viral Vector Manufacturing Market In Recent Years?

Major companies operating in the viral and non-viral vector manufacturing market are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Viral And Non-Viral Vector Manufacturing Market?

North America was the largest region in the viral and non-viral vector manufacturing market in 2025. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Viral And Non-Viral Vector Manufacturing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12570&type=smp

Browse Through More Reports Similar to the Global Viral And Non-Viral Vector Manufacturing Market 2026, By The Business Research Company

Viral Inactivation Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795